Nanomedicine

Targeted siRNA Nanotherapeutics Against Breast and Ovarian Metastatic Cancer: A Comprehensive Review of the Literature

Metastasis is considered the major cause of unsuccessful cancer therapy. The metastatic development requires tumor cells to leave their initial site, circulate in the blood stream, acclimate to new cellular environments at a remote secondary site and endure there. There are several steps in metastasis, including invasion, intravasation, circulation, extravasation, premetastatic niche formation, micrometastasis and metastatic colonization. siRNA therapeutics are appreciated for their usefulness in treatment of cancer metastasis. However, siRNA therapy as a single therapy may not be a sufficient option for control of metastasis. By combining siRNA with targeting, functional agents or small-molecule drugs have shown potential effects that enhance therapeutic effectiveness. This review addresses multidrug resistance and metastasis in breast and ovarian cancers and highlights drug-delivery strategies using siRNA therapeutics.

Redox Resetting of Cisplatin-Resistant Ovarian Cancer Cells by Cisplatin-Encapsulated Nanostructured Lipid Carriers

Intrauterine devices incorporating nanocarriers for targeted cervical cancer therapy

Viruses are key contributors to many severe human illnesses. The majority of cervical cancer cases are linked to infection with the human papillomavirus (HPV). Current antiviral drug development strategies aim to interfere either with viral components or with specific host cell mechanisms. Combining the local biochemical actions of hormonal, antiviral, and chemotherapeutic agents can help in the prevention of viral infection and cancer appearance. This work presents the injection molding of intrauterine devices (IUD) with progesterone, fluorouracil, and surfactant agents for drug delivery in prophylactic and infectious cervical cancer treatments. The IUDs were manufactured, and their properties were analyzed by electronic microscopy (SEM), infrared spectroscopy (FTIR), calorimetry (DSC), and mechanical tests. The drug release profiles and cell culture interactions were also investigated. Polyethylene-based drug-loaded IUDs showed reproducible manufacturing, sustained drug release, and promising cytotoxic and antimicrobial activity, supporting their potential for localized cervical cancer treatment.

Engineering Extracellular Vesicles Mimetics for Targeted Chemotherapy of Drug-Resistant Ovary Cancer

Nanoarchitectonics of Doxycycline-Loaded Vitamin E–D-α-Tocopheryl Polyethylene Glycol 1000 Succinate Micelles for Ovarian Cancer Stem Cell Treatment

Nanomedicine-Mediated Optimization of Immunotherapeutic Approaches in Cervical Cancer

Cervical cancer shows immense complexity at the epigenetic, genetic and cellular levels, limiting conventional treatment. Immunotherapy has revolutionized nanomedicine and rejuvenated the field of tumor immunology. Although several immunotherapeutic approaches have shown favorable clinical responses, their efficacies vary, with subsets of patients benefitting. The success of cancer immunotherapy requires the enhancement of cytokines and antitumor effector cell production and activation. Recently, the feasibility of nanoparticle-based cytokine approaches in tumor immunotherapy has been highlighted. Immunotherapeutic nanoparticle-based platforms form a novel strategy enabling researchers to co-deliver immunomodulatory agents, target tumors, improve pharmacokinetics and minimize collateral toxicity to healthy cells. This review looks at the potential of immunotherapy and nanotechnologically enhanced immunotherapeutic approaches for cervical cancer.

Synergistic Antitumor Effect of Folate-Targeted Pluronic™ F-127/Poly(Lactic Acid) Polymersomes for Codelivery of Doxorubicin and Paclitaxel

Curcumin-Reduced Gold Nanoparticles Facilitate Il-12 Delivery to A Cervical Cancer In Vitro Cell Model